Skip to content
DraconiticResearch
Search Sources API
201,642 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BY-NC-ND 4.0JACC Case Reports

Dasatinib-Induced Pulmonary Arterial Hypertension

  • Nimisha Musthafa Hafeesa1
  • Gulbadin Mufti2
  • Harikrishnan Sivadasanpillai1
  1. 1Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India
  2. 2Department of Cardiology, Kashmir Medical College and Hospital, I.E Sempora Medicity, Srinagar, Jammu and Kashmir, India
Read full textPDFDOICite

Abstract

Introduction: Pulmonary arterial hypertension (PAH) is a serious complication of dasatinib, used for the treatment of chronic myeloid leukemia. Although drug-induced PAH is a recognized entity, the timeline for onset and the degree of recovery on drug withdrawal remain poorly defined.

Case Summary: This review includes a series of 5 cases of dasatinib-induced PAH, in which PAH partially or fully reversed on discontinuation of the drug. All cases had documented normal cardiac status at baseline and developed PAH within 12-24 months of initiation. Three cases required pulmonary vasodilators in addition to discontinuation of the drug. The median time to resolution of PAH was 2 (2-4.5) months.

Conclusions: Dasatinib-induced PAH is a reversible yet serious condition, which mandates regular screening of patients for early recognition of the condition. Larger series with longer follow-up are mandated for better understanding of the factors associated with the risks and severity of the condition.

Related

  1. Multimodality imaging features of dasatinib-induced pulmonary arterial hypertension
    Chikako Awazu, Seitaro Oda, Seika Furuie +9
    Journal of Cardiology CasesPeer-reviewedCC BY 4.0Full textCardiovascular medicinePMC
  2. The Functional Molecular Biopsy: Exercise-Induced Transpulmonary Multi-Omic Profiling in Pulmonary Arterial Hypertension
    Fernanda P. Oliveira, Thais C. F. Menezes, Claudia Mickael +1
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  3. Spermidine attenuates monocrotaline-induced pulmonary arterial hypertension with HADHA-associated improvements in fatty acid oxidation and mitochondrial redox homeostasis
    Xinyu Bai, Keke Tian, Shiyuan Song +6
    Redox BiologyPeer-reviewedCC BYFull textMolecular biology & gene regulationGeneral biologyDOAJ
  4. FSP1 as the convergent hub of autophagy and ubiquitination governing ferroptosis in monocrotaline‐induced pulmonary arterial hypertension
    Dandan Chen, Qi Jin, Lei Zhang +4
    Clinical and Translational MedicinePeer-reviewedCC BY 4.0Full textOncologyPMC
  5. Sex-dependent transcriptional and imaging responses to metformin in young-adult mice with SuHx-induced pulmonary arterial hypertension
    Irene Fernández-Folgueral, María Jesús Sánchez-Guisado, Irati Aiestaran-Zelaia +9
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{hafeesa2026dasatinibinduced,
  title = {{Dasatinib-Induced Pulmonary Arterial Hypertension}},
  author = {Nimisha Musthafa Hafeesa and Gulbadin Mufti and Harikrishnan Sivadasanpillai},
  journal = {JACC Case Reports},
  year = {2026},
  month = aug,
  doi = {10.1016/j.jaccas.2026.109931},
  url = {https://doi.org/10.1016/j.jaccas.2026.109931},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Dasatinib-Induced Pulmonary Arterial Hypertension
AU  - Nimisha Musthafa Hafeesa
AU  - Gulbadin Mufti
AU  - Harikrishnan Sivadasanpillai
PY  - 2026
DA  - 2026/08/20
JO  - JACC Case Reports
DO  - 10.1016/j.jaccas.2026.109931
UR  - https://doi.org/10.1016/j.jaccas.2026.109931
AB  - Introduction: Pulmonary arterial hypertension (PAH) is a serious complication of dasatinib, used for the treatment of chronic myeloid leukemia. Although drug-induced PAH is a recognized entity, the timeline for onset and the degree of recovery on drug withdrawal remain poorly defined.  Case Summary: This review includes a series of 5 cases of dasatinib-induced PAH, in which PAH partially or fully reversed on discontinuation of the drug. All cases had documented normal cardiac status at baseline and developed PAH within 12-24 months of initiation. Three cases required pulmonary vasodilators in addition to discontinuation of the drug. The median time to resolution of PAH was 2 (2-4.5) months.  Conclusions: Dasatinib-induced PAH is a reversible yet serious condition, which mandates regular screening of patients for early recognition of the condition. Larger series with longer follow-up are mandated for better understanding of the factors associated with the risks and severity of the condition.
SN  - 2666-0849
ER  -